LGL Group (NYSEAMERICAN:LGL) Issues Earnings Results

LGL Group (NYSEAMERICAN:LGL) released its earnings results on Monday. The industrial products company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.09), reports. The company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $9.10 million. LGL Group had a net margin of 16.50% and a return on equity of 1.66%.

LGL Group Price Performance

Shares of LGL traded up $0.15 during midday trading on Wednesday, hitting $7.10. The stock had a trading volume of 3,233 shares, compared to its average volume of 12,477. The stock’s 50 day moving average is $7.14 and its 200 day moving average is $6.48. The firm has a market cap of $46.35 million, a PE ratio of 63.55 and a beta of 0.31. LGL Group has a 1 year low of $5.45 and a 1 year high of $9.74.

Institutional Trading of LGL Group

A hedge fund recently raised its stake in LGL Group stock. Osaic Holdings Inc. lifted its stake in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) by 15.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,250 shares of the industrial products company’s stock after purchasing an additional 2,710 shares during the period. Osaic Holdings Inc. owned about 0.38% of LGL Group worth $154,000 at the end of the most recent quarter. 30.28% of the stock is owned by hedge funds and other institutional investors.

LGL Group Company Profile

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.